Monte Rosa Therapeutics (NASDAQ: GLUE) insider transactions
In the twelve months to 10 November 2026, executives and directors of Monte Rosa Therapeutics reported 37 open-market sales of 207,824 shares ($4.1m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 5 October 2026 | Bowen Matthew | Principal Accounting Officer | Open-market sale | −13 | $10.56 | 25,891 | Form 4 |
| 16 July 2026 | Warmuth Markus | President & CEO | Open-market sale | −9,500 | $23.18 | 585,038 | Form 4 |
| 15 July 2026 | Champoux Jennifer | Chief Operating Officer | Option exercise | +4,351 | $3.98 | 66,722 | Form 4 |
| 15 July 2026 | Champoux Jennifer | Chief Operating Officer | Open-market sale | −4,351 | $23.38 | 62,371 | Form 4 |
| 6 July 2026 | Townson Sharon | Chief Scientific Officer | Option exercise | +6,000 | $6.14 | 73,845 | Form 4 |
| 6 July 2026 | Townson Sharon | Chief Scientific Officer | Open-market sale | −5,600 | $23.25 | 68,245 | Form 4 |
| 6 July 2026 | Townson Sharon | Chief Scientific Officer | Open-market sale | −400 | $24.13 | 67,845 | Form 4 |
| 1 July 2026 | Behbahani Ali | Director | Other | −1,000,000 | — | 6,692,298 | Form 4 |
| 1 July 2026 | Behbahani Ali | Director | Other | +15,000 | — | 15,000 | Form 4 |
| 1 July 2026 | Behbahani Ali | Director | Other | −15,000 | — | 0 | Form 4 |
| 30 June 2026 | Janku Filip | Chief Medical Officer | Option exercise | +5,407 | $13.41 | 66,019 | Form 4 |
| 30 June 2026 | Janku Filip | Chief Medical Officer | Open-market sale | −5,407 | $24.50 | 60,612 | Form 4 |
| 29 June 2026 | Manning Anthony M. | Director | Option exercise | +10,000 | $4.16 | 10,000 | Form 4 |
| 29 June 2026 | Manning Anthony M. | Director | Open-market sale | −10,000 | $23.11 | 0 | Form 4 |
| 29 June 2026 | Janku Filip | Chief Medical Officer | Option exercise | +6,000 | $7.56 | 65,992 | Form 4 |
| 29 June 2026 | Janku Filip | Chief Medical Officer | Open-market sale | −6,000 | $22.95 | 59,992 | Form 4 |
| 24 June 2026 | Janku Filip | Chief Medical Officer | Option exercise | +30,000 | $7.56 | 89,992 | Form 4 |
| 24 June 2026 | Janku Filip | Chief Medical Officer | Open-market sale | −30,000 | $21.42 | 59,992 | Form 4 |
| 23 June 2026 | Champoux Jennifer | Chief Operating Officer | Option exercise | +2,175 | $3.98 | 64,546 | Form 4 |
| 23 June 2026 | Champoux Jennifer | Chief Operating Officer | Open-market sale | −2,175 | $20.00 | 62,371 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Monte Rosa Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.